Low-Cost, High-Potential: 3 Stocks Under $5 with Surprising Upside

Low-Cost, High-Potential: 3 Stocks Under $5 with Surprising Upside

Explore stocks on Coinbase

Trading penny stocks can deliver robust returns in the blink of an eye. In the last month, Tilray Brands(NASDAQ:TLRY) stock has surged by roughly 30%. This is just one example of the ferocity of the rally in stocks under $5.

However, I believe that penny stocks with potential are not just trading ideas. In the penny stocks space, there are names that represent good business with decent fundamentals. If investors can hold these stocks patiently for three to five years, returns can be surprisingly high. In October 2022, Miniso Group (NYSE:MNSO) stock traded at $5. In September, the stock touched a high of $30. This already implies 6x returns within 24 months.

Of course, it’s easier to cite examples of the past. However, I can say with some conviction that investors will not be disappointed if they choose fundamentally sound stories. This column, therefore, discusses three stocks under $5 that look attractive from a 36 to 60-month investment horizon.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Cronos Group (CRON)

Young green medicinal marijuana plant in a pot after a rain fall shallow depth of field with focus on leaf; cannabis stocks
Young green medicinal marijuana plant in a pot after a rain fall shallow depth of field with focus on leaf; cannabis stocks

Source: gvictoria / Shutterstock.com

I believe that Cronos (NASDAQ:CRON) stock is possibly the most undervalued name among cannabis stocks. From current levels of $2.10, I expect 5x to 10x returns in the next five years. These returns are likely even if there is no federal-level legalization of cannabis.

One reason to be bullish on Cronos is the balance sheet. As of Q3 2023, Cronos reported cash and equivalents of $840 million. The company has been conserving cash and a big acquisition might be on the cards.

Further, in a federal-level legalization scenario, Cronos will be positioned to make aggressive investments. It’s worth mentioning here that cannabis can be potentially “reclassified as a Schedule III drug under the Controlled Substances Act.” This will be a big catalyst in the U.S. as “Schedule III substances are recognized as offering potential therapeutic benefits and can be obtained with a prescription.”

In September, Cronos sent its first order of cannabis to the German distribution partner, Cansativa. Further, the company plans to ship cannabis to Vitura Health Limited for sale in the Australian medical market. With new markets and the continued launch of new products, the growth outlook is positive.

Standard Lithium (SLI)

Standard Lithium logo or icon on website page, Illustrative Editorial
Standard Lithium logo or icon on website page, Illustrative Editorial

Source: Postmodern Studio / Shutterstock.com

Standard Lithium (NYSE:SLI) is another stock under $5 that can be a 10-bagger from current levels of $2.10. SLI stock looks massively undervalued after a correction of 27% for year-to-date. The correction aligns with a sharp correction in lithium prices. Once sentiments reverse, lithium stocks are poised for a big rally.